{
    "root": "2f3aacb7-ebbb-e49e-e063-6394a90a9176",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Alprazolam",
    "value": "20250228",
    "ingredients": [
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "DOCUSATE SODIUM",
            "code": "F05Q2T2JA0"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "SODIUM BENZOATE",
            "code": "OJ245FE5EU"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "ALPRAZOLAM",
            "code": "YU55MQ3IZY"
        }
    ],
    "indications": "alprazolam tablets indicated : acute treatment generalized anxiety disorder ( gad ) adults . treatment panic disorder ( pd ) , without agoraphobia adults .",
    "contraindications": "generalized anxiety disorder : ( 2.1 ) recommended starting oral 0.25 mg 0.5 mg three times daily . may increased , intervals every 3 4 days , maximum recommended daily dose 4 mg , given divided doses . lowest possible effective dose frequently assess need continued treatment . panic disorder : recommended starting oral 0.5 mg three times daily . may increased intervals every 3 4 days increments 1 mg per day . ( 2.2 ) tapering , decrease 0.5 mg every 3 days . patients may require even slower reduction . ( 2.3 , 5.2 ) full prescribing information recommended geriatric patients , patients hepatic impairment , ritonavir . ( 2.4 , 2.5 , 2.6 )",
    "warningsAndPrecautions": "alprazolam tablets , usp oral following strengths package configurations : 1 mg oval , blue tablets debossed “ gg 258 ” one side scored reverse side ndc 43063-609-30 bottles 30 ndc 43063-609-40 bottles 40 ndc 43063-609-60 bottles 60 ndc 43063-609-90 bottles 90",
    "adverseReactions": "alprazolam contraindicated patients : known hypersensitivity alprazolam benzodiazepines . angioedema reported [ ( 6.2 ) ] . taking strong cytochrome p450 3a ( cyp3a ) inhibitors ( e.g . , ketoconazole , itraconazole ) , except ritonavir [ ( 2.6 ) , ( 5.5 ) , ( 7.1 ) ]",
    "indications_original": "Alprazolam tablets are indicated for the:\n                  \n                     acute treatment of generalized anxiety disorder (GAD) in adults.\n                     treatment of panic disorder (PD), with or without agoraphobia in adults.",
    "contraindications_original": "Generalized Anxiety Disorder: ( 2.1 ) Recommended starting oral dosage is 0.25 mg to 0.5 mg three times daily. Dosage may be increased, at intervals of every 3 to 4 days, to a maximum recommended daily dose of 4 mg, given in divided doses. Use the lowest possible effective dose and frequently assess the need for continued treatment. Panic Disorder: Recommended starting oral dosage is 0.5 mg three times daily. The dosage may be increased at intervals of every 3 to 4 days in increments of no more than 1 mg per day. ( 2.2 ) When tapering, decrease dosage by no more than 0.5 mg every 3 days. Some patients may require an even slower dosage reduction. ( 2.3 , 5.2 ) See the Full Prescribing Information for the recommended dosage in geriatric patients, patients with hepatic impairment, and with use with ritonavir. ( 2.4 , 2.5 , 2.6 )",
    "warningsAndPrecautions_original": "Alprazolam tablets, USP for oral administration are in the following strengths and package configurations:\n                  1 mg\n                  Oval, blue tablets debossed “GG 258” on one side and scored on the reverse side\n                  NDC 43063-609-30 Bottles of 30\n                  NDC 43063-609-40 Bottles of 40\n                  NDC 43063-609-60 Bottles of 60\n                  NDC 43063-609-90 Bottles of 90",
    "adverseReactions_original": "Alprazolam is contraindicated in patients:\n                  \n                     with known hypersensitivity to alprazolam or other benzodiazepines. Angioedema has been reported\n  \n   [see Adverse Reactions (\n   \n    6.2)]\n  \n   .\n \n  \n                     taking strong cytochrome P450 3A (CYP3A) inhibitors (e.g., ketoconazole, itraconazole), except ritonavir\n  \n   [see Dosage and Administration (\n   \n    2.6), Warnings and Precautions (\n   \n    5.5), Drug Interactions (\n   \n    7.1)]"
}